Do you want to read an article? Please log in or register.
Correlating CFTR Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment
J Cyst Fibros.
Nagy B Jr, Bene Z, Fejes Z, Heltshe SL, Reid D, Ronan NJ, McCarthy Y, Smith D, Nagy A, Joseloff E, Balla G, Kappelmayer J, Macek M Jr, Bell SC, Plant BJ, Amaral MD, Balogh I
doi: 10.1016/j.jcf.2018.08.013.
Pulmonary Fibrosis
Effects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis
Am J Respir Crit Care Med.
Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B
doi: 10.1164/
Pulmonary Fibrosis
Initial clinical evaluation of stationary digital chest tomosynthesis in adult patients with cystic fibrosis
Eur Radiol.
Gunnell ET, Franceschi DK, Inscoe CR, Hartman A, Goralski JL, Ceppe A, Handly B, Sams C, Fordham LA, Lu J, Zhou O, Lee YZ
doi: 10.1007/s00330-018-5703-9.
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Lancet Respir Med.
Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group
doi: 10.1016/S2213-
Pulmonary Fibrosis
New treatments targeting the basic defects in cystic fibrosis
Presse Med.
Fajac I, Wainwright CE
doi: 10.1016/j.lpm.2017.01.024.
Pulmonary Fibrosis
SILDENAFIL IMPROVES VASCULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS
Am J Physiol Heart Circ Physiol.
Rodriguez Miguelez P, Seigler N, Tucker MA, Csanyi G, McKie KT, Forseen C, Harris RA
doi: 10.1152/ajpheart.00301.2018.
RECOMMENDED
Pulmonary Fibrosis
Diagnostic tools and CFTR functional assays in cystic fibrosis: utility and availability in Switzerland
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Swiss Med Wkly
Fernandez Elviro C, Blanchon S, Hoehnel S, Schumacher U, Sauty A, Brandenberg N, Regamey N
doi: 10.4414/smw.2021.20496
Asthma
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections
Clin Infect Dis.
Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P, Antimicrobial Resistance International Working Group in Cystic Fibrosis.
doi: 10.1093/cid/ciz364.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Lancet Respir Med.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group
doi: 10.1016/